Srikumar Chakravarthi

Traditional Chinese Medicine (TCM) plants have been known to confer beneficial therapeutic effects in the traditional systemic Chinese Medicinal, but a science-based verification is important to offer evidence-based utilization. This review will cover or discuss the pharmacological prospect of TCM plants, including Andrographis paniculata, Glycyrrhiza glabra, Scutellaria baicalensis, astragalus membranaceus, ginkgo biloba and panax ginseng using the preclinical study in animals. These investigations indicate a high level of antiviral, anti-inflammatory, immuno-modulator, anti-oxidant, heendoguinative proteomin and neuro-protection, which have been explained through recent pharmacognostic strategies such as phytochemical screening, chromatographic studies, in-vitro tests, as well as molecular analyses. Although translation into humans is impeded by species-specific effects, complex, formulations and reproducibility, the incorporation of standardized extracts, high- fidelity disease models, and increasing ethical options all improve the translational significance. The results indicate the possible potential in TCM plants as evidence-based human and veterinary medicines and point to possible areas of future intensive preclinical and clinical studies.